<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405323</url>
  </required_header>
  <id_info>
    <org_study_id>18453A</org_study_id>
    <nct_id>NCT04405323</nct_id>
  </id_info>
  <brief_title>Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women</brief_title>
  <official_title>Interventional, Open-label, Randomized, Two-sequence Study Evaluating the Effect of CYP3A4 Inhibition on the Pharmacokinetics, Safety and Tolerability of Lu AG06466 in Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to learn how a drug (itraconazole) that is known to inhibit a certain enzym in the
      liver, impacts the body's ability to breakdown Lu AG06466 into breakdown products in healthy
      men and women. The main breakdown product is Lu AG06988.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two sequence study where Lu AG06466 will be dosed with and without food, Sequence 1 and
      Sequence 2. Each subject will receive single oral doses of Lu AG06466. Subject will be
      randomized to one of two sequences.

      For inhibition of CYP3A4, each subject will receive a once daily dosage of itraconazole from
      Day 5 to Day 11.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-inf) Lu AG06466</measure>
    <time_frame>From 0 to 48 hours post-dose on Day 1, 3, 8 and 10</time_frame>
    <description>Area under the Lu AG06466 plasma concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) Lu AG06988</measure>
    <time_frame>From 0 to 48 hours post-dose on Day 1, 3, 8 and 10</time_frame>
    <description>Area under the Lu AG06988 plasma concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Lu AG06466</measure>
    <time_frame>From 0 to 48 hours post-dose on Day 1, 3, 8 and 10</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of Lu AG06466</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Lu AG06988</measure>
    <time_frame>From 0 to 48 hours post-dose on Day 1, 3, 8 and 10</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of Lu AG06988</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AG06466 - Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing on Days 1 and 8 will be following an overnight fast, and dosing on Days 3 and 10 will be following a standard high-fat breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG06466 - Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing on Days 1 and 8 will be following, a standard high-fat breakfast and dosing on Days 3 and 10 will be following an overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466</intervention_name>
    <description>hard capsules, orally, single doses</description>
    <arm_group_label>Lu AG06466 - Sequence 1</arm_group_label>
    <arm_group_label>Lu AG06466 - Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>200 and 300 mg, capsules, orally</description>
    <arm_group_label>Lu AG06466 - Sequence 1</arm_group_label>
    <arm_group_label>Lu AG06466 - Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a BMI ≥18.5 and ≤30 kg/m2

          -  The subject is, in the opinion of the investigator, generally healthy based on medical
             history, a physical examination, a neurological examination, vital signs, an
             electrocardiogram (ECG), and the results of the clinical chemistry, haematology,
             urinalysis, serology, and other laboratory tests.

          -  The subject must not be of childbearing potential (if a woman) or should use
             contraception (both sexes). If women, the subject must not be pregnant or
             breastfeeding.

        Exclusion Criteria:

          -  The subject is a poor metabolizer (PM) of CYP2C9 and/or CYP2C19.

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>US1517</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Email contact via H. Lundbeck A/S</last_name>
      <email>LundbeckClinicalTrials@Lundbeck.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

